Products

Biaffin

Newsletter

kinases protein kinase inhibitors signaling activators kinase substrates antibodies bioluminescence assays
ActiveMax® Recombinant Human VEGF165 (HPLC-verified), 50µg  

ActiveMax® Recombinant Human VEGF165 (HPLC-verified), 50µg

ActiveMax® Recombinant Human VEGF165, Ala 27 - Arg 191, was produced in human 293 cells (HEK293), Tag free, (HPLC-verified, MALS verified

Synonyms: Vascular endothelial growth factor A-165, VEGF-A165 cytokine, Vascular permeability factor, VPF-165

More details

VE5-H4210-050

Availability: within 7 days

402,00 €

Background:
VEGF165 is the most abundant splice variant of VEGF-A [1,2]. VEGF165 is produced by a number of cells including endothelial cells, macrophages and T cells. VEGF165 is involved in angiogenesis, vascular endothelial cell survival, growth, migration and vascular permeability [1]. VEGF gene expression is induced by hypoxia, inflammatory cytokines and oncogenes [1,2]. VEGF165 binds to heparan sulfate and is retained on the cell surface and in the extracellular matrix [2,3]. VEGF165 binds to the receptor tyrosine kinases, VEGFR1 and VEGFR2 [1]. VEGF165 is the only splice variant that binds to co-receptors NRP-1 and NRP-2 [1-3] that function to enhance VEGFR2 signaling [1]. Binding of VEGF165 to VEGFR1 and VEGFR2 leads to activation of the PI3K/AKT, p38 MAPK, FAK and paxillin [1]. VEGF plays a key role in tumor angiogenesis in many cancers [2].

Source
Recombinant ActiveMax® Human VEGF165, Tag Free (MALS verified) (VE5-H4210) is expressed from human 293 cells (HEK293). It contains AA Ala 27 - Arg 191 (Accession # P15692-4).
Predicted N-terminus: Ala 27

Molecular Characterization
This protein carries no "tag". The protein has a calculated MW of 19.2 kDa. As a result of glycosylation, the protein migrates as 24 kDa (monomer) under reducing (R) condition, and 43-50 kDa (homodimer) under non-reducing (NR) condition (SDS-PAGE).

Endotoxin
Less than 1.0 EU per μg of the ActiveMax® Human VEGF165 by the LAL method.

Purity
>98% as determined by SDS-PAGE.
>95% as determined by SEC-MALS.

Formulation
Lyophilized from 0.22 μm filtered solution in PBS, pH7.4. Normally Trehalose is added as protectant before lyophilization.

Reconstitution
See Certificate of Analysis for details of reconstitution instruction and specific concentration.

Storage
For long term storage, the product should be stored at lyophilized state at -20°C or lower.
Please avoid repeated freeze-thaw cycles.
This product is stable after storage at:
-20°C to -70°C for 24 months in lyophilized state;
-70°C for 24 months under sterile conditions after reconstitution.

Bioactivity
Please refer to product data sheet.

Clinical and Translational Updates

(1) "Unexpected Amplification of Synergistic Gene Expression to Boom Vascular Flow in Advantageous Dual-Gene Co-expression Plasmid Delivery Systems over Physically Mixed Strategy"
Wang, Gao, Zhou et al
ACS Appl Bio Mater (2020) 3 (10), 7228-7235
(2) "Hyaluronan/Collagen Hydrogels with Sulfated Glycosaminoglycans Maintain VEGF165 Activity and Fine-Tune Endothelial Cell Response"
Rother, Ruiz-Gómez, Balamurugan et al
ACS Appl Bio Mater (2021) 4 (1), 494-506
(3) "ROLE OF MICRO RNA IN THE REGULATION OF CELL POLARIZATION IN HEPATOCELLULAR CARCINOMA"
Al-Ani, Al-Ani
Hum Gene Ther (2021)
Showing 1-3 of 1207 papers.

Citations

(1) "FGF primes angioblast formation by inducing ETV2 and LMO2 via FGFR1/BRAF/MEK/ERK"
Authors: Chen PC, Hsueh YW, Lee YH, et al.
Journal: Cell Mol Life Sci 2020
Application: Flow cytometry
(2) "Creation of different bioluminescence resonance energy transfer based biosensors with high affinity to VEGF"
Authors: Stumpf C, et al
Journal: PLoS One 2020
Application: eBRET2 biosensors
(3) "Methods of producing glycosylated proteins"
Authors: ML Wetter, et al
Journal: US20180354997A1 2018
Application: SPR
(4) "A biosynthetic route for polysialylating proteins in Escherichia coli"
Authors: Keys TG, et al.
Journal: Metab Eng 2017
Application: SPR

 

The following products could also be interesting for you: